Evans Syndrome Market Research Report - Global Forecast till 2023

Evans Syndrome Market Research Report - Global Forecast till 2023

ID: MRFR/HC/3700-HCRR | | Region: Global | 85 pages | Half-Cooked Research Reports

Evans syndrome Market Information: by diagnosis (blood test, bone marrow biopsy, antibody assays, computed tomography (CT) scan, flow cytometry), treatment (Splenectomy, Pharmacologic, Biologic therapy, Stem Cell), end user – Global forecast till 2023

Market Scenario


Evans syndrome (ES), is an autoimmune disorder characterized by the subsequent or simultaneous development of autoimmune hemolytic anemia, and immune thrombocytopenia. It is classified as primary or secondary based on its association with others diseases, such as primary antiphospholipid syndrome, systemic lupus erythematous (SLE), Sjögren syndrome, Hodgkin lymphoma, IgA deficiency, and chronic lymphocytic leukemia.


According to the Centers for Disease Control & Prevention, autoimmune disorder is the third most common category of disease in the United States after heart disease and cancer. It is reported that it affects approximately 5%–8% of the population i.e. 14–22 million persons.


The severity and symptoms of Evans syndrome vary greatly from one person to another. Some patients with Evans syndrome may first show the high destruction of red blood cells (RBCs), known as anemia, and others may first show low levels of platelets, known as thrombocytopenia. Low levels of white blood cells (WBSs), known as neutropenia, is less common in individuals with Evans syndrome than thrombocytopenia or anemia.


Notably, growing public awareness is the key factor driving the Evans syndrome market. Nowadays, people are becoming more aware of the different types of autoimmune disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. People are becoming more aware and conscious of the diseases. Thus, increasing awareness has provided a push to the growth of the market.


Various other factors such as increasing incidents of autoimmune disorders, increasing government assistance, improving regulatory framework, increasing automation of laboratories and rising funding and reimbursement are continuously contributing to the growth of the global Evans syndrome market.


Despite these drivers, there are some issues associated with Evans syndrome market. Some of the challenges in research and development, side-effects of treatment, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.


It is estimated that the Evans syndrome market is expected to grow at a CAGR 10.2% during the forecast period of 2017-2023.


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities


Segmentation


The global Evans syndrome market is segmented on the basis of diagnosis, treatment, and distribution channels.


On the basis of the diagnosis, the market is classified as blood test, bone marrow biopsy, antibody assays, computed tomography (CT) scan, flow cytometry of double-negative T cells, and others. The blood test is further segmented into complete blood count (CBC), and direct antiglobulin test.


On the basis of the treatment, the market is classified as pharmacologic therapy, splenectomy,


Biologic therapy, stem cell transplantation, and others. The pharmacologic therapy is further segmented into Prednisone and intravenous immunoglobulin (IVIg) therapy. The biologic therapy is segmented into Rituximab and others.


On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.


Regional Analysis


The Americas dominate the Evans syndrome market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.


Europe holds the second position in the Evans syndrome market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.


Asia Pacific is the fastest growing Evans syndrome market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.


The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.


Key Players


Some of key the players in the global Evans syndrome market are Pfizer, Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, BD, ChemoMetec A/S, and Others.


Research Methodology

Evans Syndrome Market


Sources: Annual reports, Press release, White paper, and Company presentation


 

Table of Contents:       

Chapter 1.         Report Prologue           

Chapter 2.         Market Introduction       

2.1        Definition         

2.2        Scope of the Study      

2.2.1     Research Objective      

2.2.2     Assumptions    

2.2.3     Limitations       

Chapter 3.         Research Methodology

3.1        Introduction

3.2        Primary Research         

3.3        Secondary research      

3.4        Market Size Estimation

Chapter 4.         Market Dynamics

4.1        Drivers 

4.2        Restrains

4.3        Opportunities   

4.4        Challenges

4.5        Macroeconomic Indicators

4.6        Technology Trends & Assessment                                

Chapter 5.         Market Factor Analysis

5.1        Porter’s Five Forces Analysis

5.1.1     Bargaining Power of Suppliers  

5.1.2     Bargaining Power of Buyers

5.1.3     Threat of New Entrants 

5.1.4     Threat of Substitutes    

5.1.5     Intensity of Rivalry        

5.2        Value Chain Analysis

5.3        Investment Feasibility Analysis  

5.4        Pricing Analysis

Chapter 6.         Global Evans Syndrome Market, by Diagnosis

6.1        Introduction

6.2        Blood Test

6.2.1     Market Estimates & Forecast, 2016 – 2023

6.3        Bone Marrow Biopsy

6.3.1     Market Estimates & Forecast, 2016 – 2023

6.4        Antibody Assays

6.4.1     Market Estimates & Forecast, 2016 – 2023

6.5        Computed Tomography (CT) Scan

6.5.1     Market Estimates & Forecast, 2016 – 2023

6.6        Flow Cytometery of double-negative T cells

6.6.1     Market Estimates & Forecast, 2016 – 2023

 

Chapter 7.         Global Evans Syndrome Market, by treatment

7.1        Introduction

7.2        Pharmacologic Therapy

7.2.1     Market Estimates & Forecast, 2017 – 2023

7.3        Splenectomy

7.3.1     Market Estimates & Forecast, 2017 – 2023

7.4        Biologic therapy

7.4.1     Market Estimates & Forecast, 2017 – 2023

7.5        Stem Cell Transplantation

7.5.1     Market Estimates & Forecast, 2017 – 2023

Chapter 8.         Global Evans Syndrome Market, by Distribution Channel

8.1        Introduction

8.2        Hospitals

8.2.1     Market Estimates & Forecast, 2017 – 2023

8.3        Clinics

8.3.2     Market Estimates & Forecast, 2017 – 2023

8.4        Diagnostic Centers

8.4.1     Market Estimates & Forecast, 2017 – 2023

8.5        Drug Stores

8.5.2     Market Estimates & Forecast, 2017 – 2023

8.6        Pharmacies

8.6.2     Market Estimates & Forecast, 2017 – 2023

8.7        Others

8.7.2     Market Estimates & Forecast, 2017 – 2023

Chapter 9.         Global Evans Syndrome Market, by Region

9.1        Introduction

9.2        Americas

9.2.1     North America

9.2.1.1  U.S.

9.2.1.2  Canada

9.2.2     South America

9.3        Europe

9.3.1     Western Europe

9.3.1.1  Germany

9.3.1.2  France

9.3.1.3  Italy

9.3.1.4  Spain

9.3.1.5  U.K

9.3.1.6  Rest of Western Europe

9.3.2     Eastern Europe

9.4        Asia Pacific

9.4.1     Japan

9.4.2     China

9.4.3     India

9.4.4     Australia

9.4.5     Republic of Korea

9.4.6     Rest of Asia Pacific

9.5        The Middle East & Africa

9.5.1     United Arab Emirates

9.5.2     Saudi Arabia

9.5.3     Oman

9.5.4     Kuwait

9.5.5     Qatar

9.5.6     Rest of the Middle East & Africa

Chapter 10        Company Landscape    

10.1      Introduction      

10.2      Market Share Analysis  

10.3      Key Development & Strategies 

10.3.1   Key Developments       

Chapter 11        Company Profiles        

11.1      Pfizer

11.1.1   Company Overview      

11.1.2   Type of Causative Agents Overview      

11.1.3   Financials        

11.1.4   SWOT Analysis

11.2      Merck & Co.     

11.2.1   Company Overview      

11.2.2   Type of Causative Agents Overview      

11.2.3   Financial Overview        

11.2.4   Key Developments       

11.2.5   SWOT Analysis

11.3      Sanofi

11.3.1   Company Overview      

11.3.2   Type of Causative Agents Overview      

11.3.3   Financial Overview

11.3.4   Key Development         

11.3.5   SWOT Analysis

11.4      Astellas Pharma, Inc.

11.4.1   Company Overview      

11.4.2   Type of Causative Agents/Business Segment Overview 

11.4.3   Financial Overview        

11.4.4   Key Development         

11.4.5   SWOT Analysis

11.5      GlaxoSmithKline plc

11.5.1   Company Overview      

11.5.2   Type of Causative Agents Overview      

11.5.3   Financial overview        

11.5.4   Key Developments       

11.6      Novartis AG     

11.6.1   Company Overview      

11.6.2   Type of Causative Agents Overview      

11.6.3   Financial Overview        

11.6.4   Key Developments       

11.7      BD

11.7.1   Overview          

11.7.2   Type of Causative Agents Overview      

11.7.3   Financials        

11.7.4   Key Developments       

11.7.5   SWOT Analysis

                        11.8      Others

Chapter 12        MRFR Conclusion        

12.1      Key Findings    

12.1.1   From CEO’s View Point

12.1.2   Unmet Needs of the Market      

12.2      Key Companies to Watch         

12.3      Prediction of Evans Syndrome Industry

Chapter 13        Appendix

 

LIST OF TABLES

Table 1             Evans Syndrome Industry Synopsis, 2017 – 2023

Table 2             Evans Syndrome Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3             Evans Syndrome Market by Region, 2017 – 2023, (USD Million)

Table 4             Evans Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 5             Evans Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 6             Evans Syndrome Market by Distribution Channels, 2017 – 2023, (USD Million)

Table 7             North America Evans Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 8 North America Evans Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 9              North America Evans Syndrome Market by Distribution Channels, 2017 – 2023, (USD Million)

Table 10            US Evans Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 11            US Evans Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 12            US Evans Syndrome Market by Distribution Channels, 2017 – 2023, (USD Million)

Table 13            Canada Evans Syndrome market by Diagnosis, 2017 – 2023, (USD Million)

Table 14            Canada Evans Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 15            Canada Evans Syndrome market by Distribution Channels, 2017 – 2023, (USD Million)

Table 16            South America Evans Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 17            South America Evans Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 18            South America Evans Syndrome Market by Distribution Channels, 2017 – 2023, (USD Million)

Table 19            Europe Evans Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 20            Europe Evans Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 21            Europe Evans Syndrome Market by Distribution Channels, 2017 – 2023, (USD Million)

Table 22            Western Europe Evans Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 23            Western Europe Evans Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 24            Western Europe Evans Syndrome Market by Distribution Channels, 2017 – 2023, (USD Million)

Table 25            Eastern Europe Evans Syndrome market by Diagnosis, 2017 – 2023, (USD Million)

Table 26            Eastern Europe Evans Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 27            Eastern Europe Evans Syndrome Market by Distribution Channels, 2017 – 2023, (USD Million)

Table 28            Asia Pacific Evans Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 29            Asia Pacific Evans Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 30            Asia Pacific Evans Syndrome market by Distribution Channels, 2017 – 2023, (USD Million)

Table 31            Middle East & Africa Evans Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 32            Middle East & Africa Evans Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 33            Middle East & Africa Evans Syndrome market by Distribution Channels, 2017 – 2023, (USD Million)

 

LIST OF FIGURES

Figure 1            Research Process

Figure 2            Segmentation for Evans Syndrome Market

Figure 3            Segmentation Market Dynamics for Evans Syndrome Market

Figure 4            Global Evans Syndrome market Share, by Diagnosis 2016

Figure 5            Global Evans Syndrome market Share, by Treatment 2016

Figure 6            Global Evans Syndrome market Share, by Distribution Channels, 2016

Figure 7            Global Evans Syndrome market Share, by Region, 2016

Figure 8            North America Evans Syndrome market Share, by Country, 2016

Figure 9            Europe Evans Syndrome market Share, by Country, 2016

Figure 10          Asia Pacific Evans Syndrome market Share, by Country, 2016

Figure 11          Middle East & Africa Evans Syndrome market Share, by Country, 2016

Figure 12          Global Evans Syndrome market: Company Share Analysis, 2016 (%)

Figure 13          Pfizer: Key Financials

Figure 14          Pfizer Segmental Revenue

Figure 15          Pfizer: Geographical Revenue

Figure 16          Merck & Co.: Key Financials

Figure 17          Merck & Co.: Segmental Revenue

Figure 18          Merck & Co.: Geographical Revenue

Figure 19          Sanofi: Key Financials

Figure 20          Sanofi: Segmental Revenue

Figure 21          Sanofi: Geographical Revenue

Figure 22          Astellas Pharma, Inc.: Key Financials

Figure 23          Astellas Pharma, Inc.: Segmental Revenue

Figure 24          Astellas Pharma, Inc.: Geographical Revenue

Figure 25          GlaxoSmithKline plc: Key Financials

Figure 26          GlaxoSmithKline plc: Segmental Revenue

Figure 27          GlaxoSmithKline plc Geographical Revenue

Figure 28          Novartis AG: Key Financials

Figure 29          Novartis AG: Segmental Revenue

Figure 30          Novartis AG: Geographical Revenue

Figure 31          BD: Key Financials

Figure 32          BD: Segmental Revenue

Figure 33          BD: Geographical Revenue